Pentasa Formulation Type
Pentasa is exclusively a controlled-release (extended-release) formulation—there is no immediate-release version of this brand available. 1
Pentasa's Unique Release Mechanism
Pentasa (mesalamine) utilizes ethylcellulose-coated microgranules that provide time-dependent, controlled release of mesalamine beginning in the duodenum and continuing throughout the small intestine (jejunum, ileum) and into the colon 2. This distinguishes it from other mesalamine formulations:
- Not pH-dependent: Unlike delayed-release formulations (e.g., Asacol, Lialda), Pentasa releases drug continuously regardless of intestinal pH 1
- Begins releasing in the stomach: Studies show Pentasa releases >50% of its drug load in the stomach compartment, with continued release throughout the GI tract 3
- Approximately 20-30% systemic absorption: This is lower than unformulated mesalamine (80% absorption) but higher than azo-bonded prodrugs like sulfasalazine 1
Clinical Implications of Pentasa's Release Profile
The controlled-release mechanism means:
- Proximal small bowel delivery: Pentasa is particularly suited for Crohn's disease involving the small intestine, as it delivers active drug to the duodenum, jejunum, and ileum 4
- Continuous colonic delivery: Approximately 75% of microgranules reach the colon where further release occurs 5
- Not affected by food or diarrhea: The release pattern remains consistent regardless of GI transit time or concurrent H2 antagonist use 5
Available Formulations
Pentasa comes in capsule form only (250 mg and 500 mg strengths), containing the ethylcellulose-coated microgranules 1. The capsule shell itself is not the controlled-release mechanism—the microgranules inside provide the extended release.
Common Pitfall to Avoid
Do not confuse Pentasa's "controlled release" with immediate release. While Pentasa begins releasing drug earlier in the GI tract than pH-dependent formulations (which may seem "immediate"), it is still an extended-release product that delivers mesalamine over time throughout the intestinal tract, not as a bolus dose 1, 3.